ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
95.693,80
-1,56%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kezar Life Sciences Inc (KZR)

  7. Kezar Life Sciences Inc (KZR) Notícias

KZR

Kezar Life Sciences (KZR)

Kezar Life Sciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KZR
DataHoraFonteTítuloCódigoCompanhia
03/12/202418:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
12/11/202418:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
12/11/202418:01Business WireKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
29/10/202418:05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:KZRKezar Life Sciences Inc
28/10/202409:30Business WireKezar Life Sciences Announces 1-for-10 Reverse Stock SplitNASDAQ:KZRKezar Life Sciences Inc
17/10/202410:22Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:KZRKezar Life Sciences Inc
17/10/202409:35Business WireKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanNASDAQ:KZRKezar Life Sciences Inc
17/10/202409:30Business WireKezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE UpdateNASDAQ:KZRKezar Life Sciences Inc
10/10/202409:30Business WireKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalNASDAQ:KZRKezar Life Sciences Inc
04/10/202418:00Business WireKezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
30/09/202409:30Business WireKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsNASDAQ:KZRKezar Life Sciences Inc
04/09/202417:01Business WireKezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/08/202417:02Business WireKezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
26/07/202418:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
10/07/202417:01Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
29/05/202417:01Business WireKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
09/05/202417:01Business WireKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
06/05/202417:05Business WireKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
14/03/202417:01Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
28/02/202418:01Business WireKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:KZRKezar Life Sciences Inc
26/02/202420:30Business WireEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
14/02/202408:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KZRKezar Life Sciences Inc
17/01/202419:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
21/11/202318:01Business WireKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/11/202318:01Business WireKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
03/10/202317:10Business WireKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerNASDAQ:KZRKezar Life Sciences Inc
20/09/202321:30Dow Jones NewsStocks to Watch: FedEx, Kezar Life Sciences, TranscatNASDAQ:KZRKezar Life Sciences Inc
20/09/202319:30Business WireKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaNASDAQ:KZRKezar Life Sciences Inc
31/08/202317:01Business WireKezar Life Sciences to Participate in Three Upcoming Investor ConferencesNASDAQ:KZRKezar Life Sciences Inc
10/08/202317:01Business WireKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KZR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZUL4
AZUL PN
BOV
AZEV4
AZEVEDO PN
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
COGN3
COGNA ON
BOV
FICT3
Fictor Alimentos ON
BOV
ATOM3
ATOMPAR ON
BOV
BRFS3
BRF S/A ON
BOV
IDIV
Dividend
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados